Dynamic prognostic nutritional index could be a novel predictor of survival in lung cancer patients treated with nivolumab

MİRİLİ C., PAYDAŞ S., OĞUL A., GÖKÇAY S., BÜYÜKŞİMŞEK M., YETİŞİR A. E., ...Daha Fazla

ANNALS OF CLINICAL AND ANALYTICAL MEDICINE, cilt.11, ss.1-6, 2020 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 11
  • Basım Tarihi: 2020
  • Doi Numarası: 10.4328/acam20025
  • Dergi Adı: ANNALS OF CLINICAL AND ANALYTICAL MEDICINE
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI)
  • Sayfa Sayıları: ss.1-6
  • Çukurova Üniversitesi Adresli: Evet

Özet

Aim: Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint inhibitor antibody, restores antitumor antibody-disrupting PD-1-mediated signaling. Although it has a striking antitumor efficacy, factors predicting response, especially at the beginning of the immunotherapy are important owing to its side-effect profile and high cost. In this study, we aimed to evaluate the predictive value of the neutrophil-lymphocyte ratio (NLR), derived NLR (dNLR), prognostic nutritional index (PNI), carcinoembryonic antigen (CEA) and change of these parameters during nivolumab treatment in patients with non-small cell lung cancer (NSCLC).